Research programme: oncology therapeutics - Globavir

Drug Profile

Research programme: oncology therapeutics - Globavir

Alternative Names: GBV 4086; GBV-1012; GBV-1028; GBV-1073; GBV-2034; GBV-3019

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Globavir Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; CCR4 receptor antagonists; CXCR4 receptor antagonists; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Sep 2016 Globavir plans a phase Ia/IIb trial for Cancer in USA (Globavir, pipeline, September 2016)
  • 09 Jul 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top